Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #90160 on NorthWest Biotherapeutics Inc (NWBO)
Evaluate
12/19/16 9:53 AM
#90175 RE: TC_Trader #90160
As previously announced, the Company is seeking to move forward with multiple clinical programs, involving both DCVax-L and DCVax-Direct. The Company is pursuing completion of the current Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer as well as pursuing Phase II combination trials of DCVax-L and checkpoint inhibitor drugs, including the Phase II trial of DCVax-L and Pembrolizumab (Keytruda) for colon cancer that was previously announced. The Company is also pursuing multiple Phase II trials with DCVax-Direct for inoperable tumors, building upon the encouraging ongoing data from the Phase I trial, which included patients with 13 different types of cancers.